Abstract:Tumour immunotherapy has achieved good therapeutic effects in clinical practice. However, T cells are easily exhausted in vivo and lead to poor results of CAR‐T‐cell therapy in the treatment of solid tumours. In this manuscript, we review the reasons for T‐cell exhaustion and the development process of T‐cell exhaustion. We also review and discuss the ways to improve CAR‐T therapeutic effect through regulating T‐cell exhaustion. Tumour immunotherapy has achieved good therapeutic effects in clinical practice and has received increased attention. Cytotoxic T cells undoubtedly play an important role in tumour immunotherapy. As a revolutionary tumour immunotherapy approach, chimeric antigen receptor T‐cell (CAR‐T‐cell) therapy has made breakthroughs in the treatment of haematological cancers. However, T cells are easily exhausted in vivo, especially after they enter solid tumours. The exhaustion of T cells can lead to poor results of CAR‐T‐cell therapy in the treatment of solid tumours. Here, we review the reasons for T‐cell exhaustion and how T‐cell exhaustion develops. We also review and discuss ways to improve CAR‐T‐cell therapy effects by regulating T‐cell exhaustion.

T‐cell exhaustion in CAR‐T‐cell therapy and strategies to overcome it